Pharmaceutical

ORIN-1001 by Shanghai Fosun Pharmaceutical (Group) for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Kidney Cancer (Renal Cell Cancer).

Jul 7, 2023 - 20:00
ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Kidney Cancer (Renal Cell Cancer).
Read the original article

Tags:

Previous Article

AMG-305 by Amgen for Breast Cancer: Likelihood of Approval

Next Article

CJ-15314 by HK inno.N for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Kiniksa Pharmaceuticals sees highest patent filings and grants during April in Q2 2024

Kiniksa Pharmaceuticals sees highest patent filings and...

Jul 22, 2024

Biotechnology Equipment Manufacturers, Companies and Suppliers for the Pharmaceutical Industry

Biotechnology Equipment Manufacturers, Companies and Su...

Sep 26, 2024

Eisai signs agreement with Bliss Biopharmaceutical to develop BB-1701

Eisai signs agreement with Bliss Biopharmaceutical to d...

May 8, 2023